A Review on Probable Causes of Cardiotoxicity Caused by Common Cancer Drugs and the Role of Traditional Chinese Medicine in Prevention and Treatment

References

• Fu YH, Rao ZZ, Li RT, et al. Prediction of disease burden caused by malignant cancer in the context of risk factor control in China, 2030. Chine J Epidemiol. 2022;43(1):7. doi:10.3760/cma.j.cn112338-20210902-00705
   Google Scholar
• Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: best Practices in Diagnosis, Prevention, and Management: part 2. J Am Coll Cardiol. 2017;70(20):2536–2551. doi:10.1016/j.jacc.2017.09.1096
   PubMedGoogle Scholar
• Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502. doi:10.1038/s41569-020-0348-1
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368–4380. doi:10.1200/JCO.2002.10.088
   PubMed Web of Science ®Google Scholar
• Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol. 2013;19(31):5051–5060. doi:10.3748/wjg.v19.i31.5051
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23(15):3502–3508. doi:10.1200/JCO.2005.10.017
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792–799. doi:10.1200/JCO.2005.05.098
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–2191. doi:10.1200/JCO.2004.11.022
   PubMed Web of Science ®Google Scholar
• Laitinen M, Zachary I, Breier G, et al. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther. 1997;8(15):1737–1744. doi:10.1089/hum.1997.8.15-1737
   PubMed Web of Science ®Google Scholar
• Levy BI, Ambrosio G, Pries AR, et al. Microcirculation in hypertension: a new target for treatment? Circulation. 2001;104(6):735–740. doi:10.1161/hc3101.091158
   PubMed Web of Science ®Google Scholar
• Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14:14–24. doi:10.1158/1078-0432.CCR-07-1033
   PubMed Web of Science ®Google Scholar
• Tsai HT, Marshall JL, Weiss SR, et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol. 2013;24(6):1574–1579. doi:10.1093/annonc/mdt019
   PubMed Web of Science ®Google Scholar
• Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49(3):568–581. doi:10.1016/S0008-6363(00)00268-6
   PubMed Web of Science ®Google Scholar
• Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7(1):171–181. doi:10.1111/j.1538-7836.2008.03212.x
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717. doi:10.7326/0003-4819-91-5-710
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–2879. doi:10.1002/cncr.11407
   PubMed Web of Science ®Google Scholar
• Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16(2):545–550. doi:10.1200/JCO.1998.16.2.545
   PubMed Web of Science ®Google Scholar
• van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010;170(14):1247–1255. doi:10.1001/archinternmed.2010.233
   PubMedGoogle Scholar
• Bodley A, Liu LF, Israel M, et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res. 1989;49(21):5969–5978.
   PubMed Web of Science ®Google Scholar
• Avci H, Epikmen ET, Ipek E, et al. Protective effects of silymarin and curcumin on cyclophosphamide-induced cardiotoxicity. Exp Toxicol Pathol. 2017;69(5):317–327. doi:10.1016/j.etp.2017.02.002
   PubMedGoogle Scholar
• Iqubal A, Sharma S, Ansari MA, et al. Nerolidol attenuates cyclophosphamide-induced cardiac inflammation, apoptosis and fibrosis in Swiss Albino mice. Eur J Pharmacol. 2019;863:172666. doi:10.1016/j.ejphar.2019.172666
   PubMed Web of Science ®Google Scholar
• Abushouk AI, Ismail A, Salem AM, Afifi AM, Abdel-Daim MM. Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity. Biomed Pharmacother. 2017;90:935–946. doi:10.1016/j.biopha.2017.04.033
   PubMed Web of Science ®Google Scholar
• Gunes S, Sahinturk V, Karasati P, Sahin IK, Ayhanci A. Cardioprotective effect of selenium against cyclophosphamide-induced cardiotoxicity in rats. Biol Trace Elem Res. 2017;177:107–114. doi:10.1007/s12011-016-0858-1
   PubMed Web of Science ®Google Scholar
• Gazia MA, El-Magd MA. Ameliorative effect of cardamom aqueous extract on doxorubicin-induced cardiotoxicity in rats. Cells Tissues Organs. 2018;206(1–2):62–72. doi:10.1159/000496109
   PubMed Web of Science ®Google Scholar
• Songbo M, Lang H, Xinyong C, Bin X, Ping Z, Liang S. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett. 2019;307:41–48. doi:10.1016/j.toxlet.2019.02.013
   PubMed Web of Science ®Google Scholar
• Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26. doi:10.3389/fcvm.2020.00026
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. doi:10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51. doi:10.1056/NEJMra043186
   PubMed Web of Science ®Google Scholar
• Dias A, Claudino W, Sinha R, et al. Human epidermal growth factor antagonists and cardiotoxicity—a short review of the problem and preventative measures. Crit Rev Oncol Hematol. 2016;104:42–51. doi:10.1016/j.critrevonc.2016.04.015
   PubMed Web of Science ®Google Scholar
• Albini A, Cesana E, Donatelli F, et al. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiol. 2011;7(5):693–704. doi:10.2217/fca.11.54
   PubMedGoogle Scholar
• Nemeth BT, Varga ZV, Wu WJ, et al. Trastuzumab cardiotoxicity: from clinical trials to experimental studies. Br J Pharmacol. 2017;174(21):3727–3748. doi:10.1111/bph.13643
   PubMed Web of Science ®Google Scholar
• de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10(11):1795–1801. doi:10.1200/JCO.1992.10.11.1795
   PubMed Web of Science ®Google Scholar
• Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17(4):729–736. doi:10.1002/j.1875-9114.1997.tb03748.x
   PubMed Web of Science ®Google Scholar
• Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer. 1993;71(2):493–509. doi:10.1002/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C
   PubMed Web of Science ®Google Scholar
• Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori. 1982;68:505–510. doi:10.1177/030089168206800609
   PubMed Web of Science ®Google Scholar
• Schober C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer. 1993;72(7):2242–2247. doi:10.1002/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002;13(5):797–801. doi:10.1093/annonc/mdf035
   PubMed Web of Science ®Google Scholar
• Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol. 2008;6(1):41–48.
   PubMedGoogle Scholar
• Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75–82. doi:10.1007/s00432-007-0250-9
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082–4085. doi:10.1073/pnas.91.9.4082
   PubMed Web of Science ®Google Scholar
• Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675–1680. doi:10.1084/jem.177.6.1675
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase 2 study of 169 patients. Blood. 2001;98(2):492–494. doi:10.1182/blood.V98.2.492
   PubMed Web of Science ®Google Scholar
• Fahdi IE, Gaddam V, Saucedo JF, et al. Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol. 2004;93(8):1052–1055. doi:10.1016/j.amjcard.2003.12.061
   PubMed Web of Science ®Google Scholar
• Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98(5):1614–1615. doi:10.1182/blood.V98.5.1614
   PubMed Web of Science ®Google Scholar
• Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100(4):1168–1171. doi:10.1182/blood-2002-01-0335
   PubMed Web of Science ®Google Scholar
• Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95(8):1629–1636. doi:10.1002/cncr.10847
   PubMed Web of Science ®Google Scholar
• Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol. 2002;20(13):3042. doi:10.1200/JCO.2002.20.13.3042
   PubMed Web of Science ®Google Scholar
• Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103(5):994–999. doi:10.1002/cncr.20893
   PubMed Web of Science ®Google Scholar
• Jacobson GM, Kamath RS, Smith BJ, Goodheart MJ. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol. 2005;96(2):470–474. doi:10.1016/j.ygyno.2004.10.023
   PubMed Web of Science ®Google Scholar
• Apiyasawat S, Wongpraparut N, Jacobson L, Berkowitz H, Jacobs LE, Kotler MN. Cisplatin induced localized aortic thrombus. Echocardiography. 2003;20(2):199–200. doi:10.1046/j.1540-8175.2003.03002.x
   PubMed Web of Science ®Google Scholar
• Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99(5):503–509. doi:10.1016/S0049-3848(00)00294-2
   PubMed Web of Science ®Google Scholar
• Cool RM, Herrington JD, Wong L. Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide. Pharmacotherapy. 2002;22(9):1200–1204. doi:10.1592/phco.22.13.1200.33524
   PubMed Web of Science ®Google Scholar
• Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology. 1985;42:296–300. doi:10.1159/000226049
   PubMed Web of Science ®Google Scholar
• Lv XF, Wen RQ, Liu K, et al. Role and molecular mechanism of traditional Chinese medicine in preventing cardiotoxicity associated with chemoradiotherapy. Front Cardiovasc Med. 2022;9:1047700. doi:10.3389/fcvm.2022.1047700
   PubMed Web of Science ®Google Scholar
• Sagaonkar PS, Pattanshetty R. Effect of medical qigong therapy on distress, fatigue, and quality of life in head and neck cancer patients undergoing intensity-modulated radiation therapy: a single arm clinical trial. World J Tradit Chin Med. 2021;7:427–435. doi:10.4103/wjtcm.wjtcm_15_21
   Google Scholar
• Zheng XY, Zhang YH, Song WT, Chang D, Liu JX. Research progress on the pharmacological mechanisms of Chinese medicines that tonify Qi and activate blood against cerebral ischemia/ reperfusion injury. World J Tradit Chin Med. 2022;8:225–235. doi:10.4103/wjtcm.wjtcm_21_21
   Google Scholar
• Guo D, Cai Y, Chai D, et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65(9):631–640.
   PubMed Web of Science ®Google Scholar
• Bhagat A, Kleinerman ES. Anthracycline-Induced Cardiotoxicity: causes, Mechanisms, and Prevention. Adv Exp Med Biol. 2020;1257:181–192.
   PubMed Web of Science ®Google Scholar